Interim report January – September 2024

Regulatory

July – September 2024

  • Net asset value was SEK 4,262 million (3,212) and net asset value per share was SEK 54.59 (52.88), adjusted net asset value per share was SEK 55.91 (52.88)
  • Change in net asset value per share in the quarter was -2.7 per cent (-8.5)
  • Total fair value of shares in portfolio companies was SEK 2,993 million (2,939)
  • Change in fair value of shares in portfolio companies was SEK -121 million (-302), equivalent to -4.0 per cent (-9.9)
  • Net profit/loss amounted to SEK -117 million (-299)
  • Earnings per share before and after dilution amounted to SEK -1.50 (-4.92)

January – September 2024

  • Change in net asset value per share was -7.0 per cent (-5.4), adjusted change in net asset value per share was -4.8 per cent
  • Change in fair value of shares in portfolio companies was SEK -102 million (-299), equivalent to -3.6 per cent (-11.0).
  • Net profit/loss amounted to SEK -164 million (-301)
  • Earnings per share before and after dilution amounted to SEK -2.42 (-6.62)
  • The expense ratio amounted to 1.3 per cent (1.4)
  • Cash and cash equivalents amounted to SEK 911 million (310)

Significant events during the quarter

  • Flerie has carried out a reverse share split of 1:100, whereby 100 existing shares became 1 share, with the record date 15 July 2024.
  • Flerie increased its shareholding in Xspray Pharma and commented on FDA feedback on Dasynoc.

Shareholders, financial analysts and media are kindly invited to a webcast in English, including presentation of the quarterly results and a Q&A, today on the 16th of October 2024 at 11:00 CET.

If you wish to participate via webcast please register via the link below. Please note that it can take a few minutes to receive the confirmation e-mail with the Teams link following registration: https://events.teams.microsoft.com/event/ef8fe4b3-cc62-47ab-addd-f56de753bdff@8a6f565d-42e1-4b27-93d3-51ae5cf1e4a2

The presentation will be available after the webcast at www.flerie.com

For more information:

Ted Fjällman, CEO
Email: ir@flerie.com

Flerie in brief
Flerie is an active long-term life science investor, with a broad and diversified portfolio of innovative companies based on pioneering science. We invest in product development and commercial growth opportunities globally alongside other leading investors, focusing predominantly on private companies that are otherwise difficult to access. Flerie’s active ownership model, broad network and resources support and accelerate the development of the portfolio projects, creating value for shareholders. Flerie AB’s ordinary share is listed on Nasdaq Stockholm with the ticker FLERIE. For further information please visit www.flerie.com

This information is information that Flerie AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-10-16 08:00 CEST.

Attachments
Flerie AB Interim Report January September 2024

Documents

Links